Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
Pre-profit biotechs listed on the Hong Kong stock exchange or Shanghai’s STAR board could soon see an influx of investment as the Chinese government expands the Stock Connect channel linking financial...
Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
DISEASE CATEGORY: Neurology INDICATION: Neurology Antisense oligonucleotides that induce exon skipping in lysosomal membrane protein CLN3 could treat CLN3 Batten disease, a neurodegenerative lysosomal...
Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction. Under the deal, Merck & Co. Inc. (NYSE:MRK) will have exclusive, global rights to cancer therapies targeting dysregulation of an...
Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
Pre-profit biotechs listed on the Hong Kong stock exchange or Shanghai’s STAR board could soon see an influx of investment as the Chinese government expands the Stock Connect channel linking financial...
Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
DISEASE CATEGORY: Neurology INDICATION: Neurology Antisense oligonucleotides that induce exon skipping in lysosomal membrane protein CLN3 could treat CLN3 Batten disease, a neurodegenerative lysosomal...
Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction. Under the deal, Merck & Co. Inc. (NYSE:MRK) will have exclusive, global rights to cancer therapies targeting dysregulation of an...
